United Therapeutics

UTHR · NASDAQ🇺🇸

Overview

Earnings Dividends Seasonality Metrics

Reported earnings 28 days ago

Previous year: $95.2M

-16.3%

Research and development

Previous year: $4.74B

-1.0%

Total Assets

$7.88B

Previous year: $7.36B

+7.0%

Loading...

United Therapeutics

Unlock previous datapoints

Upgrade

United Therapeutics

Unlock previous datapoints

Upgrade

United Therapeutics Revenue by Segment

United Therapeutics Revenue by Geographic Location

Revenue by Segment

Tyvaso DPI Revenue

CapyFin.com

Nebulized Tyvaso Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

Remodulin Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

Orenitram Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

Unituxin Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

Adcirca Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

Other Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

Revenue by Geographic Location

United States Revenue

CapyFin.com

Rest of World Revenue

CapyFin.com

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Key Statistics

Market Cap

$22.8B

P/E Ratio

19.06

Sector

N/A

Industry

N/A

52-Week High

$545

52-Week Low

$274

Income tax expense

$79.7M

Research and development

$140M

SG&A expense

$191M

Share-based compensation

$39M

Basic shares outstanding

43.3M

Products

Get in Touch

Resources

United Therapeutics

United Therapeutics

United Therapeutics

United Therapeutics Revenue by Segment

United Therapeutics Revenue by Geographic Location

Revenue by Segment

Tyvaso DPI Revenue

Nebulized Tyvaso Revenue

Remodulin Revenue

Orenitram Revenue

Unituxin Revenue

Adcirca Revenue

Other Revenue

Revenue by Geographic Location

United States Revenue

Rest of World Revenue

Historical Earnings Impact

Avg. Return Before/After Earnings

Key Statistics